

Adrian V S Hill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7612716/publications.pdf>

Version: 2024-02-01

275
papers

38,420
citations

3531

90
h-index

3407

183
g-index

288
all docs

288
docs citations

288
times ranked

40168
citing authors

#	ARTICLE	IF	CITATIONS
1	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. <i>Molecular Therapy</i> , 2022, 30, 2024-2047.	8.2	14
2	Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria. <i>Frontiers in Immunology</i> , 2022, 13, 795463.	4.8	6
3	Virus-like particle vaccines. , 2022, , 163-176.		0
4	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, .	5.0	6
5	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	5.0	26
6	Identification of hostâ€“pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. <i>Nature Communications</i> , 2022, 13, 1818.	12.8	28
7	A loss-of-function <i>IFNAR1</i> allele in Polynesia underlies severe viral diseases in homozygotes. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	28
8	Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers. <i>Science</i> , 2022, 377, 72-79.	12.6	13
9	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	13.7	3,887
10	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	30.7	265
11	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	30.7	473
12	Malaria is a cause of iron deficiency in African children. <i>Nature Medicine</i> , 2021, 27, 653-658.	30.7	35
13	COVIDâ€“19 vaccines for rapid global impact. <i>BJU International</i> , 2021, 127, 137-139.	2.5	1
14	Low immunogenicity of malaria preâ€“erythrocytic stages can be overcome by vaccination. <i>EMBO Molecular Medicine</i> , 2021, 13, e13390.	6.9	7
15	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	13.7	979
16	Safety and Immunogenicity of Adenovirus and Poxvirus Vected Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021, 9, 262.	4.4	3
17	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	13.7	540
18	Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice. <i>Scientific Reports</i> , 2021, 11, 10792.	3.3	10

#	ARTICLE	IF	CITATIONS
19	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 1809-1818.	13.7	253
20	Dissection-independent production of <i>Plasmodium</i> sporozoites from whole mosquitoes. <i>Life Science Alliance</i> , 2021, 4, e202101094.	2.8	2
21	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021, 12, 4636.	12.8	31
22	Screening of viral-vectored <i>P. falciparum</i> pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites. <i>PLoS ONE</i> , 2021, 16, e0254498.	2.5	2
23	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , the, 2021, 8, e474-e485.	4.7	190
24	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	12.4	80
25	Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to <i>P. falciparum</i> Transmission-Blocking Candidate PfS25 in Humans. <i>Frontiers in Immunology</i> , 2021, 12, 732667.	4.8	6
26	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	30.7	900
27	Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. , 2021, 9, e003218.		10
28	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet</i> , The, 2021, 398, 981-990.	13.7	214
29	Paths and timings of the peopling of Polynesia inferred from genomic networks. <i>Nature</i> , 2021, 597, 522-526.	27.8	31
30	Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation. <i>Scientific Reports</i> , 2021, 11, 20877.	3.3	2
31	Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes. <i>Frontiers in Genetics</i> , 2021, 12, 719791.	2.3	7
32	Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus. <i>Genes and Immunity</i> , 2020, 21, 63-70.	4.1	5
33	Vaccine innovations for emerging infectious diseases—a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2020, 1462, 14-26.	3.8	15
34	Identification of antigens presented by MHC for vaccines against tuberculosis. <i>Npj Vaccines</i> , 2020, 5, 2.	6.0	69
35	Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 108-125.	4.1	34
36	Immunological considerations for SARS-CoV-2 human challenge studies. <i>Nature Reviews Immunology</i> , 2020, 20, 715-716.	22.7	13

#	ARTICLE	IF	CITATIONS
37	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	13.7	2,080
38	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	13.7	1,196
39	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	31
40	The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans. <i>Scientific Reports</i> , 2020, 10, 9004.	3.3	9
41	Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency. <i>BMC Medicine</i> , 2020, 18, 148.	5.5	4
42	Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 270.	3.9	14
43	Estimating the burden of iron deficiency among African children. <i>BMC Medicine</i> , 2020, 18, 31.	5.5	47
44	Native American gene flow into Polynesia predating Easter Island settlement. <i>Nature</i> , 2020, 583, 572-577.	27.8	64
45	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928.		27
46	Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria. <i>Infection and Immunity</i> , 2020, 88, .	2.2	7
47	Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule. <i>Scientific Reports</i> , 2020, 10, 5716.	3.3	9
48	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 816-826.	9.1	182
49	TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16479-16488.	7.1	43
50	Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. <i>Npj Vaccines</i> , 2019, 4, 44.	6.0	31
51	The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. <i>Science Advances</i> , 2019, 5, eaaw0109.	10.3	20
52	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. <i>Journal of Infectious Diseases</i> , 2019, 219, 1187-1197.	4.0	59
53	A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 96.	3.9	27
54	Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. <i>Vaccines</i> , 2019, 7, 40.	4.4	19

#	ARTICLE	IF	CITATIONS
55	Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. <i>Vaccines</i> , 2019, 7, 33.	4.4	23
56	Iron Status and Associated Malaria Risk Among African Children. <i>Clinical Infectious Diseases</i> , 2019, 68, 1807-1814.	5.8	38
57	Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and <i>Toxoplasma gondii</i> . <i>PLoS ONE</i> , 2019, 14, e0210407.	2.5	18
58	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. <i>Scientific Reports</i> , 2018, 8, 3390.	3.3	34
59	Language continuity despite population replacement in Remote Oceania. <i>Nature Ecology and Evolution</i> , 2018, 2, 731-740.	7.8	91
60	Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3601-E3603.	7.1	12
61	Risk of nontyphoidal <i>Salmonella</i> bacteraemia in African children is modified by STAT4. <i>Nature Communications</i> , 2018, 9, 1014.	12.8	29
62	DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 107.	2.5	7
63	First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. <i>PLoS ONE</i> , 2018, 13, e0208328.	2.5	53
64	CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. <i>Frontiers in Immunology</i> , 2018, 9, 1660.	4.8	26
65	Prime and target immunization protects against liver-stage malaria in mice. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	68
66	Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses. <i>Scientific Reports</i> , 2018, 8, 15020.	3.3	18
67	A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006870.	3.0	40
68	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, 49.	6.0	51
69	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018, 9, 2441.	12.8	69
70	Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. <i>Vaccines</i> , 2018, 6, 50.	4.4	54
71	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018, 201, 1315-1326.	0.8	30
72	Tailoring a <i>Plasmodium vivax</i> Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. <i>Infection and Immunity</i> , 2018, 86, .	2.2	39

#	ARTICLE	IF	CITATIONS
73	Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. <i>Scientific Reports</i> , 2018, 8, 3896.	3.3	15
74	The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver. <i>Journal of Immunology</i> , 2017, 198, 2006-2016.	0.8	17
75	Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. <i>Vaccine Journal</i> , 2017, 24, .	3.1	20
76	Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis. <i>Science Advances</i> , 2017, 3, e1602096.	10.3	46
77	Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. <i>Molecular Therapy</i> , 2017, 25, 547-559.	8.2	34
78	Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. <i>Scientific Reports</i> , 2017, 7, 46482.	3.3	41
79	Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania. <i>Nature Communications</i> , 2017, 8, 14946.	12.8	114
80	Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. <i>Scientific Reports</i> , 2017, 7, 46621.	3.3	158
81	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. <i>Vaccine</i> , 2017, 35, 3780-3788.	3.8	133
82	Cryopreservation-related loss of antigen-specific IFN γ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. <i>Vaccine</i> , 2017, 35, 1898-1906.	3.8	40
83	Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 328-339.	5.6	178
84	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 3020-3032.	3.3	67
85	Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M α . <i>Vaccine</i> , 2017, 35, 6208-6217.	3.8	27
86	Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. <i>Scientific Reports</i> , 2017, 7, 7284.	3.3	13
87	An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens. <i>Scientific Reports</i> , 2017, 7, 17011.	3.3	15
88	Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. <i>Frontiers in Immunology</i> , 2017, 8, 1551.	4.8	23
89	Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. <i>JCI Insight</i> , 2017, 2, .	5.0	78
90	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. <i>Vaccines</i> , 2016, 4, 27.	4.4	35

#	ARTICLE	IF	CITATIONS
91	Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS ONE, 2016, 11, e0167951.	2.5	46
92	Chronic hepatitis C viral infection subverts vaccine-induced T _H 1 cell immunity in humans. Hepatology, 2016, 63, 1455-1470.	7.3	43
93	Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Vaccine, 2016, 34, 2296-2298.	3.8	28
94	Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Scientific Reports, 2016, 6, 20617.	3.3	98
95	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular Therapy, 2016, 24, 1470-1477.	8.2	52
96	Viral vectors as vaccine platforms: from immunogenicity to impact. Current Opinion in Immunology, 2016, 41, 47-54.	5.5	137
97	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01_BWith Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781.	4.0	96
98	Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. American Journal of Human Genetics, 2016, 98, 1092-1100.	6.2	39
99	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646.	27.0	295
100	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine, 2016, 34, 49-55.	3.8	13
101	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2016, 16, 31-42.	9.1	187
102	Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respiratory Medicine, the, 2016, 4, 259-271.	10.7	536
103	Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Scientific Reports, 2015, 5, 16756.	3.3	36
104	Malaria vaccines: identifying Plasmodium falciparum liver-stage targets. Frontiers in Microbiology, 2015, 6, 965.	3.5	21
105	Rare Variants in MYD88, IRAK4 and IKBKG and Susceptibility to Invasive Pneumococcal Disease: A Population-Based Case-Control Study. PLoS ONE, 2015, 10, e0123532.	2.5	8
106	Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PflUIS3, PflSA1 and PflSAP2 in Multiple Strains of Mice. PLoS ONE, 2015, 10, e0144515.	2.5	5
107	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naïve Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086.	4.0	110
108	Variants in the Mannose-binding Lectin Gene <i>MBL2</i> do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort. Clinical Infectious Diseases, 2015, 61, 695-703.	5.8	24

#	ARTICLE	IF	CITATIONS
109	Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1254-1259.	1.4	5
110	Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respiratory Medicine, the, 2015, 3, 53-60.	10.7	166
111	The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine, 2015, 33, 1121-1128.	3.8	20
112	Genomic modulators of gene expression in human neutrophils. Nature Communications, 2015, 6, 7545.	12.8	120
113	Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Scientific Reports, 2015, 5, 11820.	3.3	49
114	Genetic susceptibility to invasive Salmonella disease. Nature Reviews Immunology, 2015, 15, 452-463.	22.7	81
115	Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malaria Journal, 2015, 14, 33.	2.3	39
116	Searching for the human genetic factors standing in the way of universally effective vaccines. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140341.	4.0	38
117	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726.	21.4	310
118	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against <i>Plasmodium falciparum</i> infection in Kenyan adults. Science Translational Medicine, 2015, 7, 286re5.	12.4	113
119	Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. Vaccine, 2015, 33, 3248-3255.	3.8	30
120	Workshop report: Malaria vaccine development in Europe—preparing for the future. Vaccine, 2015, 33, 6137-6144.	3.8	15
121	Profiling the host response to malaria vaccination and malaria challenge. Vaccine, 2015, 33, 5316-5320.	3.8	21
122	Progress with viral vectored malaria vaccines: A multi-stage approach involving ‘unnatural immunity’. Vaccine, 2015, 33, 7444-7451.	3.8	53
123	Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells. PLoS ONE, 2015, 10, e0119880.	2.5	17
124	Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain. PLoS ONE, 2014, 9, e100538.	2.5	33
125	4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques. PLoS ONE, 2014, 9, e105520.	2.5	7
126	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science Translational Medicine, 2014, 6, 261ra153.	12.4	297

#	ARTICLE	IF	CITATIONS
127	Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. <i>Molecular Therapy</i> , 2014, 22, 668-674.	8.2	165
128	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. <i>Molecular Therapy</i> , 2014, 22, 464-475.	8.2	188
129	Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to <i>Plasmodium falciparum</i> using sporozoites administered by intramuscular injection. <i>Frontiers in Microbiology</i> , 2014, 5, 686.	3.5	95
130	Efficacy of a <i>Plasmodium vivax</i> Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic <i>Plasmodium berghei</i> Parasites. <i>Infection and Immunity</i> , 2014, 82, 1277-1286.	2.2	53
131	RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events. <i>Journal of Immunology</i> , 2014, 192, 5963-5973.	0.8	38
132	Analysis of human B cell responses following C<h>A<d63>MVA MSP<1> and AMA<1> immunization and controlled malaria infection. <i>Immunology</i> , 2014, 141, 628-644.	4.4	43
133	Towards a multi-antigen multi-stage malaria vaccine. <i>Malaria Journal</i> , 2014, 13, .	2.3	7
134	Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. <i>Vaccine Journal</i> , 2014, 21, 901-903.	3.1	12
135	Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. <i>Molecular Therapy</i> , 2014, 22, 233-238.	8.2	101
136	Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. <i>Molecular Therapy</i> , 2014, 22, 2142-2154.	8.2	68
137	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naïve to Malaria-endemic Populations. <i>Molecular Therapy</i> , 2014, 22, 1992-2003.	8.2	49
138	Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. <i>Scientific Reports</i> , 2014, 4, 6154.	3.3	46
139	External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. <i>PLoS ONE</i> , 2014, 9, e97398.	2.5	28
140	Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. <i>PLoS ONE</i> , 2014, 9, e107903.	2.5	65
141	A Phase 1a Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. <i>PLoS ONE</i> , 2014, 9, e115161.	2.5	48
142	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013, 4, 2836.	12.8	256
143	Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice. <i>Virology Journal</i> , 2013, 10, 349.	3.4	51
144	Identifying Recent Adaptations in Large-Scale Genomic Data. <i>Cell</i> , 2013, 152, 703-713.	28.9	325

#	ARTICLE	IF	CITATIONS
145	Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling. PLoS Pathogens, 2013, 9, e1003303.	4.7	70
146	Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. Journal of Infectious Diseases, 2013, 208, 340-345.	4.0	53
147	Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. Journal of Immunology, 2013, 190, 1135-1147.	0.8	23
148	The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment. Scientific Reports, 2013, 3, 1706.	3.3	36
149	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe. PLoS ONE, 2013, 8, e65960.	2.5	80
150	Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice. PLoS ONE, 2013, 8, e67888.	2.5	66
151	Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. PLoS ONE, 2013, 8, e57726.	2.5	64
152	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. Journal of Infectious Diseases, 2012, 205, 772-781.	4.0	194
153	Recombinant Viral-Vectored Vaccines Expressing Plasmodium chabaudi Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection. Journal of Immunology, 2012, 188, 5041-5053.	0.8	29
154	Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. Science Translational Medicine, 2012, 4, 115ra2.	12.4	257
155	Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza Vaccine, MVA-NP+M1, in Humans. Clinical Infectious Diseases, 2012, 55, 19-25.	5.8	224
156	Bayesian refinement of association signals for 14 loci in 3 common diseases. Nature Genetics, 2012, 44, 1294-1301.	21.4	469
157	ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Molecular Therapy, 2012, 20, 2355-2368.	8.2	196
158	Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies. Travel Medicine and Infectious Disease, 2012, 10, 192-196.	3.0	10
159	Evolution, revolution and heresy in the genetics of infectious disease susceptibility. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 840-849.	4.0	117
160	Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. Human Vaccines and Immunotherapeutics, 2012, 8, 706-714.	3.3	73
161	Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity. Molecular Therapy, 2012, 20, 1633-1647.	8.2	37
162	Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates. PLoS ONE, 2012, 7, e33555.	2.5	43

#	ARTICLE	IF	CITATIONS
163	Identification of 34 Novel Proinflammatory Proteins in a Genome-Wide Macrophage Functional Screen. PLoS ONE, 2012, 7, e42388.	2.5	9
164	T Cell Responses Induced by Adenoviral Vected Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. PLoS ONE, 2012, 7, e44943.	2.5	23
165	A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. PLoS ONE, 2012, 7, e48322.	2.5	107
166	Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. Science Translational Medicine, 2012, 4, 115ra1.	12.4	356
167	Human genetic susceptibility to infectious disease. Nature Reviews Genetics, 2012, 13, 175-188.	16.3	413
168	Coated microneedle arrays for transcutaneous delivery of live virus vaccines. Journal of Controlled Release, 2012, 159, 34-42.	9.9	141
169	Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnology and Bioengineering, 2012, 109, 719-728.	3.3	44
170	Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. PLoS ONE, 2012, 7, e31208.	2.5	157
171	Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials. PLoS ONE, 2012, 7, e38434.	2.5	66
172	A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE, 2012, 7, e40385.	2.5	301
173	Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection. PLoS ONE, 2012, 7, e50447.	2.5	23
174	The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nature Communications, 2011, 2, 601.	12.8	233
175	A human Phase I/IIa malaria challenge trial of a polypeptide malaria vaccine. Vaccine, 2011, 29, 7514-7522.	3.8	46
176	Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1. PLoS ONE, 2011, 6, e20977.	2.5	45
177	Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice. PLoS ONE, 2011, 6, e22442.	2.5	68
178	Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology, 2011, 23, 377-382.	5.5	188
179	Vaccines and global health. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2733-2742.	4.0	25
180	CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria. Journal of Immunology, 2011, 187, 1347-1357.	0.8	110

#	ARTICLE	IF	CITATIONS
181	Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference. Journal of Immunology, 2011, 187, 3738-3750.	0.8	41
182	Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Molecular Therapy, 2011, 19, 2269-2276.	8.2	156
183	Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases, 2011, 52, 1-7.	5.8	424
184	Vaccines against malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2806-2814.	4.0	165
185	The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. Journal of Immunology, 2011, 187, 2602-2616.	0.8	55
186	Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS ONE, 2011, 6, e22271.	2.5	84
187	Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass. Science Translational Medicine, 2010, 2, 19ra12.	12.4	139
188	Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. Nature Genetics, 2010, 42, 739-741.	21.4	332
189	Prime-boost vectored malaria vaccines: Progress and prospects. Hum Vaccin, 2010, 6, 78-83.	2.4	184
190	An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6. Human Molecular Genetics, 2010, 19, 720-730.	2.9	23
191	Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 ⁺ T-Cell Responses. Infection and Immunity, 2010, 78, 145-153.	2.2	178
192	Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine, 2010, 29, 256-265.	3.8	67
193	Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines. Journal of Immunology, 2010, 185, 7583-7595.	0.8	76
194	Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in <i>Mycobacterium tuberculosis</i> -infected Individuals. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 724-733.	5.6	107
195	Consanguinity and susceptibility to infectious diseases in humans. Biology Letters, 2009, 5, 574-576.	2.3	62
196	Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. Cell Host and Microbe, 2009, 5, 95-105.	11.0	65
197	Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. Vaccine, 2009, 27, 5589-5598.	3.8	19
198	Jenner reborn: a new vaccine institute. Lancet, The, 2009, 373, 445-446.	13.7	0

#	ARTICLE	IF	CITATIONS
199	Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against <i>Plasmodium berghei</i> . European Journal of Immunology, 2008, 38, 732-741.	2.9	95
200	Effective induction of high-titer antibodies by viral vector vaccines. Nature Medicine, 2008, 14, 819-821.	30.7	148
201	Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial. PLoS ONE, 2008, 3, e1493.	2.5	99
202	Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA). PLoS ONE, 2008, 3, e1638.	2.5	87
203	Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa. PLoS ONE, 2008, 3, e2921.	2.5	45
204	The Induction and Persistence of T Cell IFN- γ Responses after Vaccination or Natural Exposure Is Suppressed by <i>Plasmodium falciparum</i> . Journal of Immunology, 2007, 179, 4193-4201.	0.8	88
205	Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. Infection and Immunity, 2007, 75, 5819-5826.	2.2	43
206	Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS ONE, 2007, 2, e707.	2.5	57
207	A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine, 2006, 24, 2850-2859.	3.8	86
208	PTPN22 and invasive bacterial disease. Nature Genetics, 2006, 38, 499-500.	21.4	54
209	Pre-erythrocytic malaria vaccines: towards greater efficacy. Nature Reviews Immunology, 2006, 6, 21-32.	22.7	125
210	Aspects of Genetic Susceptibility to Human Infectious Diseases. Annual Review of Genetics, 2006, 40, 469-486.	7.6	244
211	A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS Clinical Trials, 2006, 1, e29.	3.5	124
212	Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein. Infection and Immunity, 2006, 74, 2706-2716.	2.2	62
213	Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage <i>Plasmodium falciparum</i> Correlate with Parasitological and Clinical Outcomes. Journal of Immunology, 2006, 177, 5736-5745.	0.8	138
214	Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 + T cell responses. Immunology and Cell Biology, 2005, 83, 307-312.	2.3	49
215	Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology, 2005, 41, 1383-1390.	7.3	125
216	Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites. Journal of Infectious Diseases, 2005, 191, 619-626.	4.0	152

#	ARTICLE	IF	CITATIONS
217	Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers. <i>Journal of Immunology</i> , 2005, 174, 449-455.	0.8	143
218	Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. <i>Journal of Immunology</i> , 2005, 175, 7264-7273.	0.8	89
219	Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria. <i>Journal of Immunology</i> , 2005, 175, 5675-5680.	0.8	123
220	Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4836-4841.	7.1	228
221	Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. <i>Vaccine</i> , 2005, 23, 857-864.	3.8	72
222	Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. <i>Journal of Immunology</i> , 2005, 175, 599-606.	0.8	60
223	QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 191-198.	1.4	96
224	Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 191-8.	1.4	71
225	A <i>Plasmodium falciparum</i> candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 290-295.	7.1	59
226	Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. <i>Nature Medicine</i> , 2004, 10, 1240-1244.	30.7	538
227	Quantitative Association Tests of Immune Responses to Antigens of <i>Mycobacterium Tuberculosis</i> : A Study of Twins in West Africa. <i>Twin Research and Human Genetics</i> , 2004, 7, 578-588.	1.0	3
228	Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. <i>Nature Medicine</i> , 2003, 9, 729-735.	30.7	536
229	Clinical Evaluation of New Immunisation Strategies for Enhancing T Cell Responses against <i>M. Tuberculosis</i> . <i>Clinical Science</i> , 2003, 104, 51P-51P.	0.0	0
230	Identification of Susceptibility Genes for Tuberculosis in Southern and West Africans Using Family-Based Linkage Analysis and Linkage Disequilibrium Mapping. <i>Clinical Science</i> , 2003, 104, 56P-56P.	0.0	0
231	EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 421-430.	1.4	34
232	Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of <i>Plasmodium falciparum</i> infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 421-30.	1.4	23
233	Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. <i>Vaccine</i> , 2002, 20, 1039-1045.	3.8	156
234	THE GENOMICS AND GENETICS OF HUMAN INFECTIOUS DISEASES SUSCEPTIBILITY. <i>Annual Review of Genomics and Human Genetics</i> , 2001, 2, 373-400.	6.2	227

#	ARTICLE	IF	CITATIONS
235	Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet, The, 2001, 358, 1927-1934.	13.7	485
236	Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis. Infection and Immunity, 2001, 69, 681-686.	2.2	213
237	Induction of CD8 + T lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. Immunology and Cell Biology, 2001, 79, 569-575.	2.3	21
238	Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. Journal of Medical Virology, 2001, 65, 664-670.	5.0	24
239	A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nature Genetics, 2001, 27, 439-441.	21.4	171
240	Genetics of susceptibility to human infectious disease. Nature Reviews Genetics, 2001, 2, 967-977.	16.3	447
241	High frequencies of circulating IFN- γ -secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. European Journal of Immunology, 2000, 30, 2713-2721.	2.9	94
242	Improved method for distinguishing the human source of mosquito blood meals between close family members. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 572-574.	1.8	23
243	In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nature Medicine, 2000, 6, 337-342.	30.7	521
244	Vaccines against intracellular infections requiring cellular immunity. Nature, 2000, 406, 793-798.	27.8	334
245	Severe Malarial Anemia and Cerebral Malaria Are Associated with Different Tumor Necrosis Factor Promoter Alleles. Journal of Infectious Diseases, 1999, 179, 287-290.	4.0	231
246	Defence by diversity. Nature, 1999, 398, 668-669.	27.8	38
247	Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunological Reviews, 1999, 170, 29-38.	6.0	179
248	Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nature Medicine, 1999, 5, 565-571.	30.7	96
249	Potent Induction of Focused Th1-type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a Recombinant Plasmodium falciparum Malaria Vaccine. Journal of Infectious Diseases, 1999, 180, 1656-1664.	4.0	148
250	The Immunogenetics of Resistance to Malaria. Proceedings of the Association of American Physicians, 1999, 111, 272-277.	2.0	54
251	Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine, 1998, 4, 397-402.	30.7	640
252	Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. European Journal of Immunology, 1998, 28, 4345-4355.	2.9	80

#	ARTICLE	IF	CITATIONS
253	Glucose-6-phosphate dehydrogenase deficiency and malaria. <i>Journal of Molecular Medicine</i> , 1998, 76, 581-588.	3.9	210
254	THE IMMUNOGENETICS OF HUMAN INFECTIOUS DISEASES. <i>Annual Review of Immunology</i> , 1998, 16, 593-617.	21.8	513
255	Protection from <i>Plasmodium berghei</i> infection by priming and boosting T _H 1 cells to a single class II-restricted epitope with recombinant carriers suitable for human use. <i>European Journal of Immunology</i> , 1998, 28, 4345-4355.	2.9	6
256	Heterogeneity of Microsatellite Mutations Within and Between Loci, and Implications for Human Demographic Histories. <i>Genetics</i> , 1998, 148, 1269-1284.	2.9	154
257	Genetic analysis of host-parasite coevolution in human malaria. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1997, 352, 1317-1325.	4.0	70
258	A protein particle vaccine containing multiple malaria epitopes. <i>Nature Biotechnology</i> , 1997, 15, 1280-1284.	17.5	153
259	Heterozygote advantage for HLA class-II type in hepatitis B virus infection. <i>Nature Genetics</i> , 1997, 17, 11-12.	21.4	291
260	A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. <i>Immunogenetics</i> , 1997, 45, 229-232.	2.4	15
261	T-cell receptor variable alpha (TCRAV) polymorphisms in European, Chinese, South American, AfroCaribbean, and Gambian populations. <i>Immunogenetics</i> , 1997, 47, 124-130.	2.4	5
262	Genetic susceptibility to multifactorial diseases. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997, 91, 369-371.	1.8	1
263	Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. <i>BMJ: British Medical Journal</i> , 1997, 315, 96-97.	2.3	66
264	Cytotoxic T lymphocytes to <i>Plasmodium falciparum</i> epitopes in an area of intense and perennial transmission in Tanzania. <i>European Journal of Immunology</i> , 1996, 26, 773-779.	2.9	54
265	Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. <i>European Journal of Immunology</i> , 1996, 26, 1951-1959.	2.9	89
266	HIV and HLA: Confusion or complexity?. <i>Nature Medicine</i> , 1996, 2, 395-396.	30.7	34
267	Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. <i>European Journal of Immunology</i> , 1995, 25, 1783-1787.	2.9	44
268	Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. <i>Nature Medicine</i> , 1995, 1, 374-375.	30.7	62
269	Variation in the TNF- α promoter region associated with susceptibility to cerebral malaria. <i>Nature</i> , 1994, 371, 508-511.	27.8	1,169
270	Maintenance of MHC polymorphism. <i>Nature</i> , 1992, 355, 403-403.	27.8	15

#	ARTICLE	IF	CITATIONS
271	Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature, 1992, 360, 434-439.	27.8	638
272	Common West African HLA antigens are associated with protection from severe malaria. Nature, 1991, 352, 595-600.	27.8	1,494
273	Human genetic susceptibility to infectious disease. , 0, .		1
274	New Malaria Vaccines: The DNA-MVA Prime-Boost Strategy. , 0, , 87-96.		0
275	Production of a high purity, C�tagged Hepatitis B surface Antigen fusion protein VLP vaccine for malaria expressed in <i>Pichia pastoris</i> under cGMP conditions. Biotechnology and Bioengineering, 0, , .	3.3	1